Home » Larry Mahan » Chairman and CEO John Poulter announced the appointment of Dr. Larry Mahan as the new CEO of OB Pharmaceuticals (OB).

Chairman and CEO John Poulter announced the appointment of Dr. Larry Mahan as the new CEO of OB Pharmaceuticals (OB).

posted in: John Poulter, Larry Mahan 0

Chairman and CEO John Poulter announced the appointment of Dr. Larry Mahan as the new CEO of OB Pharmaceuticals (OB).

LONDON, ONTARIO April 2, 2018 -- Chairman and CEO John Poulter announced the appointment of Dr. Larry Mahan as the new CEO of OB Pharmaceuticals (OB). Dr. Mahan served previously on the company's advisory board and later as VP Business Development providing preclinical, clinical and strategic business development direction.

"The Board of Directors is pleased to have Larry increase his role as CEO within OB. Over the past few years Larry’s guidance has been invaluable to the company", remarked John Poulter. "Given his experience in the industry and his detailed knowledge of OB’s operations his evolution to this new role is natural. As the company begins to move its focus from our own labs and onto the stage of Investigative New Drug status it is critical that the company is led by professionals with deep industry experience. The board is unanimous in the belief that Larry’s is well suited to navigate OB toward its next important milestones. It is contemplated that Larry will be invited to sit on OB’s board where I will continue with the role of Chairman."

Dr. Mahan received his PhD in Physiology and Pharmacology from the University of California, San Diego and went on to post-graduate work at the NIH under a prestigious Pharmacology Research Associate Traineeship in the laboratory of Nobel Laureate Dr. Julius Axelrod (NIMH). His 12-year career at NIMH and later NINDS focused on molecular neuropharmacology and the identification and characterization of neurotransmitter receptors using expression cloning technologies. Following, he cofounded TherExcell, Inc. with Dr. Michael Poulter and others in Vancouver, BC while a guest researcher at the National Research Council, Ottawa, ON. Moving from research, Dr. Mahan served three administrations as Director of Biosciences for the State of Maryland's biopharmaceutical industry, undertaking global business development initiatives, creating entrepreneurial assistance programs and providing diligence oversight for bioscience investments by the State's public venture fund. In addition, he later served as Director of Innovation and Business Development for Children's National Medical Center and its newly formed $150M Institute for Pediatric Surgical Innovation and Children's Research Institute to identify and accelerate promising research programs for commercialization and expand Children's intellectual property portfolio. Dr. Mahan joined OB Pharmaceuticals advisory board in 2016.

About OB Pharmaceuticals

OB Pharmaceuticals is an early stage biopharmaceutical company dedicated to improving the lives of individuals through the development of first-in-class therapeutics for more effective prevention and management of epilepsy and other related seizure disorders.